查找临床试验
已按「地中海贫血」检索，对应国际通用词 thalassemia
共找到 26 项正在招募的试验（在中国／港澳台设有中心）
数据更新于 00:19，每 5 分钟自动同步Β-Thalassemia Treatment with KL003 Cell Injection
China
年龄 3 Years – 35 Years
Kanglin Biotechnology (Hangzhou) Co., Ltd.
Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent β-thalassemia
China
年龄 6 Years – 35 Years
Shanghai BDgene Co., Ltd.
Long-term Follow-up Study of BRL-101 for TDT
China
年龄 3 Years – 35 Years
Bioray Laboratories
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
United States、Australia、Belgium、Bulgaria、Canada 等 12 国
年龄 18 Years – 不限
Celgene
A Study Evaluating the Safety and Efficacy of the GMCN-508A Drug Product in Transfusion-dependent α-Thalassemia Participants
China
年龄 5 Years – 35 Years
First Affiliated Hospital of Guangxi Medical University
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
United States、China、Germany、Greece、India 等 9 国
年龄 6 Years – 17 Years
Celgene
Low-Dose Liposomal Amphotericin B for Invasive Fungal Infection Prophylaxis in Neutropenic Children
China
年龄 3 Years – 17 Years
Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia
China
年龄 18 Years – 65 Years
Kind Pharmaceuticals LLC
the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia
China
年龄 18 Years – 35 Years
Shenzhen Hemogen
A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia
China
年龄 18 Years – 65 Years
Mabwell (Shanghai) Bioscience Co., Ltd.
the Safety and Efficacy Evaluation of HGI-002 Injection in Patients With Transfusion-Dependent α-Thalassemia
China
年龄 12 Years – 35 Years
Shenzhen Hemogen
Clinical Study of Super Transplantation in the Treatment of Severe β-thalassemia
China
年龄 7 Years – 10 Years
Guangzhou Women and Children's Medical Center